Motif Bio plc Announces Voluntary Delisting from the Nasdaq Capital Market
26 nov. 2019 02h00 HE
|
Motif Bio plc
NEW YORK, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB) ("Motif Bio" or the "Company") announces that formal notice was given by the Company to Nasdaq on November 25, 2019 of...
Motif Bio and Hercules Capital Amend Loan and Security Agreement
02 sept. 2019 02h00 HE
|
Motif Bio plc
NEW YORK, Sept. 02, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB) ("Motif Bio" or the "Company"), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics,...
NIH to Evaluate Iclaprim Activity against Listeria
19 août 2019 02h00 HE
|
Motif Bio plc
NEW YORK, Aug. 19, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the...
Motif Bio and Hercules Capital Amend Loan and Security Agreement
01 août 2019 02h00 HE
|
Motif Bio plc
NEW YORK, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that its...
Motif Bio Confirms Receipt of Deficiency Notice from Nasdaq
26 juil. 2019 02h00 HE
|
Motif Bio plc
NEW YORK, July 26, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that it has...
Motif Bio Confirms Meeting Date with U.S. FDA regarding Iclaprim
26 juil. 2019 02h00 HE
|
Motif Bio plc
NEW YORK, July 26, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the U.S....
Motif Bio Announces Receipt of Deficiency Notice from Nasdaq
19 juil. 2019 02h00 HE
|
Motif Bio plc
NEW YORK, July 19, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that it has...
Motif Bio Submits Meeting Request and Package to the U.S. FDA for Iclaprim
15 juil. 2019 02h00 HE
|
Motif Bio plc
NEW YORK, July 15, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that it has...
Motif Bio Presents New Iclaprim Data at ASM Microbe 2019
24 juin 2019 02h00 HE
|
Motif Bio plc
NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today reported that new...
Motif Bio Announces Path Forward for Iclaprim following Receipt of FDA Meeting Minutes
06 juin 2019 02h00 HE
|
Motif Bio plc
NEW YORK, June 06, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the...